{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:40:19Z","timestamp":1791510019219,"version":"4.3.4"},"reference-count":174,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02331","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:30:36Z","timestamp":1570149036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":64,"title":["The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid"],"prefix":"10.3389","volume":"10","author":[{"given":"Kelly N.","family":"Messingham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler P.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12026-009-8153-2","article-title":"The prevalence of 30 ICD-10 autoimmune diseases in Denmark","volume":"47","author":"Eaton","year":"2010","journal-title":"Immunol Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/ddg.12612","article-title":"S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Schmidt","year":"2015","journal-title":"J Dtsch Dermatol Ges."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in germany","volume":"136","author":"Hubner","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2018.08.030","article-title":"Prevalence estimates for pemphigoid in the United States: a sex-adjusted and age-adjusted population analysis","volume":"80","author":"Wertenteil","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.iac.2012.04.002","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"32","author":"Schmidt","year":"2012","journal-title":"Immunol Allergy Clin North Am."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"Della Torre","year":"2012","journal-title":"Br J Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jama.1967.03120220053008","article-title":"Basement zone antibodies in bullous pemphigoid","volume":"200","author":"Jordon","year":"1967","journal-title":"J Am Med Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1365-4632.2008.03824.x","article-title":"Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis","volume":"47","author":"Barnadas","year":"2008","journal-title":"Int J Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1172\/JCI113803","article-title":"Isolation of complementary-DNA for bullous pemphigoid antigen by use of patients autoantibodies","volume":"82","author":"Stanley","year":"1988","journal-title":"J Clin Investig."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1172\/JCI114812","article-title":"Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome","volume":"86","author":"Diaz","year":"1990","journal-title":"J Clin Investig."},{"key":"B14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00441-014-2061-z","article-title":"Molecular architecture and function of the hemidesmosome","volume":"360","author":"Walko","year":"2015","journal-title":"Cell Tissue Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2133.1995.tb02665.x","article-title":"Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia","volume":"133","author":"Fairley","year":"1995","journal-title":"Br J Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/exd.12877","article-title":"One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1","volume":"25","author":"Kunzli","year":"2016","journal-title":"Exp Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1600-0625.2009.00948.x","article-title":"Animal models for autoimmune bullous dermatoses","volume":"19","author":"Bieber","year":"2010","journal-title":"Exp Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of Disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment","volume":"129","author":"Iwata","year":"2009","journal-title":"J Investig Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4049\/jimmunol.1001753","article-title":"FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid","volume":"187","author":"Messingham","year":"2011","journal-title":"J Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ajpath.2012.11.029","article-title":"Bullous pemphigoid IgG induces BP180 internalization via a macropinocytic pathway","volume":"182","author":"Hiroyasu","year":"2013","journal-title":"Am J Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.1400095","article-title":"Bullous pemphigoid autoantibodies directly induce blister formation without complement activation","volume":"193","author":"Ujiie","year":"2014","journal-title":"J Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jaut.2008.08.009","article-title":"Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model","volume":"31","author":"Liu","year":"2008","journal-title":"J Autoimmun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5792","DOI":"10.4049\/jimmunol.1003402","article-title":"Antibodies to pathogenic epitopes on type XVII collagen cause skin fragility in a complement-dependent and -independent manner","volume":"188","author":"Natsuga","year":"2012","journal-title":"J Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.iac.2012.04.001","article-title":"Pathogenesis of bullous pemphigoid","volume":"32","author":"Ujiie","year":"2012","journal-title":"Immunol Allergy Clin North Am."},{"key":"B30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2133.2008.08858.x","article-title":"IgE autoantibodies against the intracellular domain of BP180","volume":"160","author":"Dresow","year":"2009","journal-title":"Br J Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.0022-202X.2005.23853.x","article-title":"Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid","volume":"125","author":"Fairley","year":"2005","journal-title":"J Investig Dermatol."},{"key":"B32","first-page":"193","article-title":"Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin","volume":"18","author":"Provost","year":"1974","journal-title":"Clin Exp Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archderm.1974.01630090016003","article-title":"IgE levels in sera of patients with pemphigus or bullous pemphigoid","volume":"110","author":"Arbesman","year":"1974","journal-title":"Arch Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review","volume":"310","author":"Saniklidou","year":"2018","journal-title":"Arch Dermatol Res."},{"key":"B35","first-page":"186","article-title":"Exploring mechanisms of IgE-mediated autoimmunity through the lens of bullous pemphigoid","volume":"151","author":"Messingham","year":"2016","journal-title":"G Ital Dermatol Venereol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1586\/1744666X.2016.1123092","article-title":"IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases","volume":"12","author":"Van Beek","year":"2016","journal-title":"Expert Rev Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"Van Beek","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1684\/ejd.2018.3366","article-title":"Immunoglobulin E and bullous pemphigoid","volume":"28","author":"Cozzani","year":"2018","journal-title":"Eur J Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1001\/jamadermatol.2016.4593","article-title":"Immunoglobulin E autoantibodies in bullous pemphigoid detected by immunoglobulin E enzyme-linked immunosorbent assays","volume":"153","author":"Hashimoto","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.1365-2133.2000.03661.x","article-title":"IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis","volume":"143","author":"Christophoridis","year":"2000","journal-title":"Br J Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1067\/mjd.2000.103986","article-title":"IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity","volume":"42","author":"Dopp","year":"2000","journal-title":"J Am Acad Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid","volume":"120","author":"Dimson","year":"2003","journal-title":"J Investig Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jim.2009.04.013","article-title":"A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid","volume":"346","author":"Messingham","year":"2009","journal-title":"J Immunol Methods."},{"key":"B44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clim.2012.02.003","article-title":"IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses","volume":"143","author":"Fania","year":"2012","journal-title":"Clin Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1046\/j.0926-9959.2001.00275.x","article-title":"Bullous pemphigoid in Liguria: a 2-year survey","volume":"15","author":"Cozzani","year":"2001","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","article-title":"Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid","volume":"49","author":"Ishiura","year":"2008","journal-title":"J Dermatol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2340\/00015555-2101","article-title":"Enzyme-linked immunoassay index for anti-NC16a IgG and IgE auto-antibodies correlates with severity and activity of bullous pemphigoid","volume":"96","author":"Kalowska","year":"2016","journal-title":"Acta Derm Venereol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1111\/bjd.12161","article-title":"Detection of IgG and IgE reactivity to BP180 using the ISAC(R) microarray system","volume":"168","author":"Pomponi","year":"2013","journal-title":"Br J Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e107725","DOI":"10.1371\/journal.pone.0107725","article-title":"Human eosinophils express the high affinity IgE receptor, fcepsilonRI, in bullous pemphigoid","volume":"9","author":"Messingham","year":"2014","journal-title":"PLoS ONE."},{"key":"B50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/bjd.15114","article-title":"Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1023\/A:1020531005776","article-title":"IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230)","volume":"18","author":"Ghohestani","year":"1998","journal-title":"J Clin Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1006\/cyto.2000.0791","article-title":"Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation","volume":"13","author":"Engineer","year":"2001","journal-title":"Cytokine."},{"key":"B53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2340\/0001555564243246","article-title":"Serum IgE levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies","volume":"64","author":"Asbrink","year":"1984","journal-title":"Acta Derm Venereol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000248663","article-title":"Clinical, histological and immunological studies in 50 patients with bullous pemphigoid","volume":"176","author":"Hadi","year":"1988","journal-title":"Dermatologica."},{"key":"B55","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.4049\/jimmunol.157.8.3642","article-title":"IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid","volume":"157","author":"Delaporte","year":"1996","journal-title":"J Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","article-title":"Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid","volume":"144","author":"Iwata","year":"2008","journal-title":"Arch Dermatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jdermsci.2016.03.009","article-title":"High serum anti-BP180 IgE levels correlate to prominent urticarial lesions in patients with bullous pemphigoid","volume":"83","author":"Cho","year":"2016","journal-title":"J Dermatol Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00403-015-1598-3","article-title":"Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid","volume":"307","author":"Bing","year":"2015","journal-title":"Arch Dermatol Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2015.01.013","article-title":"In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases","volume":"78","author":"Moriuchi","year":"2015","journal-title":"J Dermatol Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jdermsci.2015.02.015","article-title":"Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients","volume":"78","author":"Ma","year":"2015","journal-title":"J Dermatol Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2015.02.009","article-title":"Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid","volume":"78","author":"Kamiya","year":"2015","journal-title":"J Dermatol Sci."},{"key":"B62","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2340\/0001555577236","article-title":"Anti-230 kDa circulating IgE in bullous pemphigoid: relationship with disease activity","volume":"77","author":"Cozzani","year":"1997","journal-title":"Acta Derm Venereol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1365-2133.2011.10481.x","article-title":"Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis","volume":"165","author":"Yayli","year":"2011","journal-title":"Br J Dermatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjd.15416","article-title":"Clinical significance of immunoglobulin E in bullous pemphigoid","volume":"177","author":"Hammers","year":"2017","journal-title":"Br J Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2133.1992.tb11833.x","article-title":"Serum IgE antibodies bind to the epidermal side of the basement membrane zone splits in bullous pemphigoid","volume":"126","author":"Parodi","year":"1992","journal-title":"Br J Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1111\/bjd.15924","article-title":"IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants","volume":"177","author":"Freire","year":"2017","journal-title":"Br J Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nri2072","article-title":"New developments in FcepsilonRI regulation, function and inhibition","volume":"7","author":"Kraft","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.imlet.2011.08.004","article-title":"Soluble IgE receptors\u2013elements of the IgE network","volume":"141","author":"Platzer","year":"2011","journal-title":"Immunol Lett."},{"key":"B69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jdermsci.2004.03.009","article-title":"Elevated expression of CD23 on peripheral blood B lymphocytes from patients with bullous pemphigoid: correlation with increased serum IgE","volume":"35","author":"Inaoki","year":"2004","journal-title":"J Dermatol Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/0923-1811(94)90089-2","article-title":"Elevated serum levels of IgE-binding factor\/soluble CD23 in bullous pemphigoid","volume":"7","author":"Furukawa","year":"1994","journal-title":"J Dermatol Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.1346-8138.1995.tb03394.x","article-title":"Serum levels of soluble CD23 in patients with bullous pemphigoid","volume":"22","author":"Maekawa","year":"1995","journal-title":"J Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/archderm.1995.01690200106030","article-title":"High levels of soluble CD23 in blister fluid of patients with bullous pemphigoid","volume":"131","author":"Schmidt","year":"1995","journal-title":"Arch Dermatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaci.2016.03.042","article-title":"CD23 surface density on B cells is associated with IgE levels and determines IgE-facilitated allergen uptake, as well as activation of allergen-specific T cells","volume":"139","author":"Selb","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/iid3.72","article-title":"High affinity targeting of CD23 inhibits IgE synthesis in human B cells","volume":"3","author":"Fellmann","year":"2015","journal-title":"Immun Inflamm Dis."},{"key":"B75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/07853890701449354","article-title":"Triggers of IgE class switching and allergy development","volume":"39","author":"Poulsen","year":"2007","journal-title":"Ann Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.it.2014.11.002","article-title":"IgE responses in mouse and man and the persistence of IgE memory","volume":"36","author":"Gould","year":"2015","journal-title":"Trends Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jaci.2007.05.033","article-title":"Association of IL-5 cytokine production and in vivo IgE levels in infants and parents","volume":"120","author":"Crestani","year":"2007","journal-title":"J Allergy Clin Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaci.2012.07.025","article-title":"Human vs. Mouse Eosinophils: \u201cThat which we call an eosinophil, by any other name would stain as red\u201d","volume":"130","author":"Lee","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF02507102","article-title":"Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid","volume":"288","author":"Schmidt","year":"1996","journal-title":"Arch Dermatol Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1046\/j.0022-202x.2001.01505.x","article-title":"Skin-homing interleukin-4 and\u221213-producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin-10-producing cells","volume":"117","author":"Teraki","year":"2001","journal-title":"J Invest Dermatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0923-1811(02)00067-1","article-title":"Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid","volume":"30","author":"Giomi","year":"2002","journal-title":"J Dermatol Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2006.03.014","article-title":"Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines","volume":"120","author":"Gounni Abdelilah","year":"2006","journal-title":"Clin Immunol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1365-2133.2006.07601.x","article-title":"Serum chemokine profile in patients with bullous pemphigoid","volume":"156","author":"Nakashima","year":"2007","journal-title":"Br J Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B85","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hyb.2011.0102","article-title":"Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180","volume":"31","author":"Messingham","year":"2012","journal-title":"Hybridoma."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","article-title":"IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice","volume":"127","author":"Zone","year":"2007","journal-title":"J Invest Dermatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"8163803","DOI":"10.1155\/2016\/8163803","article-title":"IgE-related chronic diseases and anti-IgE-based treatments","volume":"2016","author":"Navines-Ferrer","year":"2016","journal-title":"J Immunol Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.anai.2014.04.002","article-title":"Changing roles of eosinophils in health and disease","volume":"113","author":"Furuta","year":"2014","journal-title":"Annals Allergy Asthma Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fimmu.2017.00484","article-title":"Eosinophils in autoimmune diseases","volume":"8","author":"Diny","year":"2017","journal-title":"Front Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0065-2776(08)01003-1","article-title":"Biology of the eosinophil","volume":"101","author":"Blanchard","year":"2009","journal-title":"Adv Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nri3341","article-title":"Eosinophils: changing perspectives in health and disease","volume":"13","author":"Rosenberg","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/exd.13416","article-title":"Eosinophils as putative therapeutic targets in bullous pemphigoid","volume":"26","author":"Simon","year":"2017","journal-title":"Exp Dermatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J Allergy Clin Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1165\/rcmb.2010-0335OC","article-title":"MHC Class II and CD9 in human eosinophils localize to detergent-resistant membrane microdomains","volume":"46","author":"Akuthota","year":"2012","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3389\/fimmu.2014.00570","article-title":"Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity","volume":"5","author":"Davoine","year":"2014","journal-title":"Front Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2222.2008.02958.x","article-title":"Eosinophils: biological properties and role in health and disease","volume":"38","author":"Hogan","year":"2008","journal-title":"Clin Exp Allergy."},{"key":"B103","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1189\/jlb.0108058","article-title":"Human eosinophils constitutively express multiple Th1, Th2, and immunoregulatory cytokines that are secreted rapidly and differentially","volume":"85","author":"Spencer","year":"2009","journal-title":"J Leukoc Biol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2014.00496","article-title":"Eosinophil secretion of granule-derived cytokines","volume":"5","author":"Spencer","year":"2014","journal-title":"Front Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fmed.2018.00201","article-title":"The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease","volume":"5","author":"Amber","year":"2018","journal-title":"Front Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00062752-200101000-00006","article-title":"Eosinophil granule proteins and their role in disease","volume":"8","author":"Walsh","year":"2001","journal-title":"Curr Opin Hematol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1067\/mai.2000.110164","article-title":"Systemic activation of basophils and eosinophils: markers and consequences","volume":"106","author":"Bochner","year":"2000","journal-title":"J Allergy Clin Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nm.1855","article-title":"Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense","volume":"14","author":"Yousefi","year":"2008","journal-title":"Nat Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1182\/blood-2012-05-432088","article-title":"Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans","volume":"121","author":"Ueki","year":"2013","journal-title":"Blood."},{"key":"B110","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11882-016-0634-5","article-title":"Eosinophil ETosis and DNA Traps: a new look at eosinophilic inflammation","volume":"16","author":"Ueki","year":"2016","journal-title":"Curr Allergy Asthma Rep."},{"key":"B111","first-page":"897","article-title":"Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins","volume":"148","author":"Borrego","year":"1996","journal-title":"Am J Pathol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1046\/j.1365-2133.2000.03599.x","article-title":"Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia","volume":"143","author":"Wakugawa","year":"2000","journal-title":"Br J Dermatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0190-9622(83)70073-3","article-title":"Bullous pemphigoid: a cause of peripheral blood eosinophilia","volume":"8","author":"Bushkell","year":"1983","journal-title":"J Am Acad Dermatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2133.1994.tb02909.x","article-title":"Bullous pemphigoid in a 19-year-old woman. A case with unusual target antigens","volume":"130","author":"Mori","year":"1994","journal-title":"Br J Dermatol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.4049\/jimmunol.179.2.1264","article-title":"Eotaxin-1\/CC chemokine ligand 11: a novel eosinophil survival factor secreted by human pulmonary artery endothelial cells","volume":"179","author":"Farahi","year":"2007","journal-title":"J Immunol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/000155500750012162","article-title":"Increased coexpression of eotaxin and interleukin 5 in bullous pemphigoid","volume":"80","author":"Shrikhande","year":"2000","journal-title":"Acta Derm Venereol."},{"key":"B117","first-page":"27","article-title":"Increased expression of eotaxin and its specific receptor CCR3 in bullous pemphigoid","volume":"12","author":"Frezzolini","year":"2002","journal-title":"Eur J Dermatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2249.2011.04464.x","article-title":"Up-regulation of CCL11 and CCL26 is associated with activated eosinophils in bullous pemphigoid","volume":"166","author":"Gunther","year":"2011","journal-title":"Clin Exp Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s004030050272","article-title":"IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid: correlations with eosinophil cationic protein, RANTES, IgE and disease severity","volume":"290","author":"D'auria","year":"1998","journal-title":"Arch Dermatol Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","article-title":"Eosinophil granule proteins: form and function","volume":"289","author":"Acharya","year":"2014","journal-title":"J Biol Chem."},{"key":"B121","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/0190-9622(93)70170-X","article-title":"Granulocyte activation in bullous diseases: release of granular proteins in bullous pemphigoid and pemphigus vulgaris","volume":"29","author":"Czech","year":"1993","journal-title":"J Am Acad Dermatol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-4362.1995.tb01562.x","article-title":"Serum eosinophil cationic protein (ECP) in bullous pemphigoid","volume":"34","author":"Caproni","year":"1995","journal-title":"Int J Dermatol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/exd.12883","article-title":"Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid","volume":"25","author":"Messingham","year":"2016","journal-title":"Exp Dermatol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.1038\/s41598-017-04687-5","article-title":"Eosinophil Cationic Protein (ECP), a predictive marker of bullous pemphigoid severity and outcome","volume":"7","author":"Giusti","year":"2017","journal-title":"Sci Rep."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1172\/JCI117196","article-title":"92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen","volume":"93","author":"Stahle-Backdahl","year":"1994","journal-title":"J Clin Invest."},{"key":"B126","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.4049\/jimmunol.0900055","article-title":"Eosinophil ribonucleases and their cutaneous lesion-forming activity","volume":"183","author":"Plager","year":"2009","journal-title":"J Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaci.2010.11.002","article-title":"Eosinophil extracellular DNA traps in skin diseases","volume":"127","author":"Simon","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"De Graauw","year":"2017","journal-title":"Allergy."},{"key":"B129","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1001\/archderm.1972.01620140010004","article-title":"Electron microscopic study of bullous pemphigoid","volume":"106","author":"Schaumburg-Lever","year":"1972","journal-title":"Arch Dermatol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/j.1365-2133.1980.tb01683.x","article-title":"Cellular events leading to blister formation in bullous pemphigoid","volume":"103","author":"Dubertret","year":"1980","journal-title":"Br J Dermatol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/1523-1747.ep12505711","article-title":"Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient","volume":"78","author":"Dvorak","year":"1982","journal-title":"J Invest Dermatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/0738-081X(87)90057-5","article-title":"The molecular pathogenesis of bullous pemphigoid","volume":"5","author":"Wintroub","year":"1987","journal-title":"Clin Dermatol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"464","DOI":"10.2340\/00015555-2581","article-title":"Increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid","volume":"97","author":"Engmann","year":"2017","journal-title":"Acta Derm Venereol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"936545","DOI":"10.1155\/2014\/936545","article-title":"Mediators of mast cells in bullous pemphigoid and dermatitis herpetiformis","volume":"2014","author":"Zebrowska","year":"2014","journal-title":"Mediators Inflamm."},{"key":"B135","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1398-9995.2004.00469.x","article-title":"Cytokine-regulated accumulation of eosinophils in inflammatory disease","volume":"59","author":"Lampinen","year":"2004","journal-title":"Allergy."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/exd.13782","article-title":"Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes","volume":"27","author":"Amber","year":"2018","journal-title":"Exp Dermatol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/eji.1830270527","article-title":"Allergen-induced recruitment of Fc\u03c3RI+ eosinophils in human atopic skin","volume":"27","author":"Barata","year":"1997","journal-title":"Eur J Immunol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1046\/j.1365-2567.1998.00418.x","article-title":"High-affinity immunoglobulin E receptor (Fc epsilon RI)-bearing eosinophils, mast cells, macrophages and Langerhans' cells in allergen-induced late-phase cutaneous reactions in atopic subjects","volume":"93","author":"Ying","year":"1998","journal-title":"Immunology."},{"key":"B139","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0091-6749(00)90081-2","article-title":"Blood eosinophils from atopic donors express messenger RNA for the \u03b1, \u03b2, and \u03b3 subunits of the high-affinity IgE receptor (Fc\u03f5RI) and intracellular, but not cell surface, \u03b1 subunit protein","volume":"105","author":"Smith","year":"2000","journal-title":"J Allergy Clin Immunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3892\/ijmm.7.3.249","article-title":"Activation of Fc epsilon RI-positive eosinophils in bullous pemphigoid","volume":"7","author":"Kasahara-Imamura","year":"2001","journal-title":"Int J Mol Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00403-017-1736-1","article-title":"Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis","volume":"309","author":"Liu","year":"2017","journal-title":"Arch Dermatol Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1526-0968.2003.00017.x","article-title":"Peptide based adsorbers for therapeutic immunoadsorption","volume":"7","author":"Ronspeck","year":"2003","journal-title":"Ther Apher Dial."},{"key":"B144","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2018.12.007","article-title":"Pharmacological advances in pemphigoid","volume":"46","author":"Maglie","year":"2019","journal-title":"Curr Opin Pharmacol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","article-title":"Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series","volume":"71","author":"Kasperkiewicz","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/ddg.13642","article-title":"Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption","volume":"16","author":"Hubner","year":"2018","journal-title":"J Dtsch Dermatol Ges."},{"key":"B147","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fmed.2018.00027","article-title":"IgE-selective immunoadsorption for severe atopic dermatitis","volume":"5","author":"Kasperkiewicz","year":"2018","journal-title":"Front Med."},{"key":"B148","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s12192-014-0513-8","article-title":"Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes","volume":"19","author":"Tukaj","year":"2014","journal-title":"Cell Stress Chaperones."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.jaci.2016.01.016","article-title":"Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis","volume":"137","author":"Reich","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fimmu.2018.00254","article-title":"Targeting IgE antibodies by immunoadsorption in atopic dermatitis","volume":"9","author":"Kasperkiewicz","year":"2018","journal-title":"Front Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1468-3083.2010.03889.x","article-title":"Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients","volume":"25","author":"Lourari","year":"2011","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fimmu.2018.00248","article-title":"Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases","volume":"9","author":"Lamberts","year":"2018","journal-title":"Front Immunol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1185\/0300799019117010","article-title":"Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality","volume":"17","author":"Holgate","year":"2001","journal-title":"Curr Med Res Opin."},{"key":"B156","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1164\/ajrccm.164.supplement_1.2103025","article-title":"Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders","volume":"164","author":"Schulman","year":"2001","journal-title":"Am J Respir Crit Care Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jaci.2007.11.026","article-title":"Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy","volume":"121","author":"Corren","year":"2008","journal-title":"J Allergy Clin Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/DDDT.S49409","article-title":"Omalizumab, an anti-immunoglobulin E antibody: state of the art","volume":"8","author":"Incorvaia","year":"2014","journal-title":"Drug Des Dev Ther."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br J Dermatol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jaci.2016.02.027","article-title":"Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses","volume":"138","author":"Gauvreau","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaad.2015.11.030","article-title":"Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up","volume":"74","author":"Ahmed","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3389\/fimmu.2017.01669","article-title":"Anti-idiotypic Antibodies against BP-IgG prevent type XVII collagen depletion","volume":"8","author":"Kamaguchi","year":"2017","journal-title":"Front Immunol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/BF01541086","article-title":"In vitro synthesis of human IgE is suppressed by human IgG","volume":"15","author":"Haas","year":"1995","journal-title":"J Clin Immunol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0091-6749(98)70130-7","article-title":"Intravenous immunoglobulin inhibits IgE production in human B lymphocytes","volume":"102","author":"Sigman","year":"1998","journal-title":"J Allergy Clin Immunol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/0091-6749(91)90420-S","article-title":"An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma","volume":"87","author":"Mazer","year":"1991","journal-title":"J Allergy Clin Immunol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1172\/JCI110750","article-title":"Regulation of immunoglobulin E antibody synthesis in man by antiidiotypic antibodies","volume":"71","author":"Geha","year":"1983","journal-title":"J Clin Invest."},{"key":"B170","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0091-6749(94)70053-2","article-title":"Possible dual role of anti-idiotypic antibodies in combined passive and active immunotherapy in honeybee sting allergy","volume":"93","author":"Boutin","year":"1994","journal-title":"J Allergy Clin Immunol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoiddupilumab for the treatment of recalcitrant bullous pemphigoid letters","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study","author":"Simon","year":"2019","journal-title":"Allergy."},{"key":"B174","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02331\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T03:09:55Z","timestamp":1695265795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02331\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":174,"alternative-id":["10.3389\/fimmu.2019.02331"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02331","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"article-number":"2331"}}